Overview

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Status:
NOT_YET_RECRUITING

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.

Phase:

PHASE2

Details

Lead Sponsor:

Bentley J. Bobrow

Collaborator:

Akebia Therapeutics Inc.

Treatments:

vadadustat